Lanean...
Temozolomide and Pituitary Tumors: Current Understanding, Unresolved Issues, and Future Directions
Temozolomide, an alkylating agent, initially used in the treatment of gliomas was expanded to include pituitary tumors in 2006. After 12 years of use, temozolomide has shown a notable advancement in pituitary tumor treatment with a remarkable improvement rate in the 5-year overall survival and 5-yea...
Gorde:
| Argitaratua izan da: | Front Endocrinol (Lausanne) |
|---|---|
| Egile Nagusiak: | , , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
Frontiers Media S.A.
2018
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6013558/ https://ncbi.nlm.nih.gov/pubmed/29963012 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fendo.2018.00318 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|